{"title":"小儿核心结合因子-急性髓性白血病细胞和分子遗传异常的预后意义","authors":"M. Yi","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.02.013","DOIUrl":null,"url":null,"abstract":"Core binding factor-acute myeloid leukemia (CBF-AML) is a common cellular genetic subtype in children with acute myeloid leukemia (AML), accounting for 25%-30% of AML, and it has a good clinical prognosis. However, there are still 30%-40% of CBF-AML patients with recurrence, and the cellular molecular genetic abnormal events accompanying such patients may be related to their clinical prognosis. At present, dasatinib has been reported in the therapy of adult CBF-AML. Different molecular genetic backgrounds have become a new idea for precise targeted therapy, but there are still few related studies on pediatric CBF-AML. The author summarizes clinical prognostic impacts of cellular and molecular genetic abnormalities which are commonly seen in pediatric CBF-AML, aiming to provide new ideas for individualized treatment of pediatric CBF-AML. \n \n \nKey words: \nCore binding factors; Leukemia, myeloid, acute; Chromosome aberrations; Prognosis; Child","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"42 1","pages":"160-164"},"PeriodicalIF":0.0000,"publicationDate":"2019-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic significance of cellular and molecular genetic abnormalities in pediatric core binding factor-acute myeloid leukemia\",\"authors\":\"M. Yi\",\"doi\":\"10.3760/CMA.J.ISSN.1673-419X.2019.02.013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Core binding factor-acute myeloid leukemia (CBF-AML) is a common cellular genetic subtype in children with acute myeloid leukemia (AML), accounting for 25%-30% of AML, and it has a good clinical prognosis. However, there are still 30%-40% of CBF-AML patients with recurrence, and the cellular molecular genetic abnormal events accompanying such patients may be related to their clinical prognosis. At present, dasatinib has been reported in the therapy of adult CBF-AML. Different molecular genetic backgrounds have become a new idea for precise targeted therapy, but there are still few related studies on pediatric CBF-AML. The author summarizes clinical prognostic impacts of cellular and molecular genetic abnormalities which are commonly seen in pediatric CBF-AML, aiming to provide new ideas for individualized treatment of pediatric CBF-AML. \\n \\n \\nKey words: \\nCore binding factors; Leukemia, myeloid, acute; Chromosome aberrations; Prognosis; Child\",\"PeriodicalId\":13774,\"journal\":{\"name\":\"国际输血及血液学杂志\",\"volume\":\"42 1\",\"pages\":\"160-164\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-03-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"国际输血及血液学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.02.013\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.02.013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Prognostic significance of cellular and molecular genetic abnormalities in pediatric core binding factor-acute myeloid leukemia
Core binding factor-acute myeloid leukemia (CBF-AML) is a common cellular genetic subtype in children with acute myeloid leukemia (AML), accounting for 25%-30% of AML, and it has a good clinical prognosis. However, there are still 30%-40% of CBF-AML patients with recurrence, and the cellular molecular genetic abnormal events accompanying such patients may be related to their clinical prognosis. At present, dasatinib has been reported in the therapy of adult CBF-AML. Different molecular genetic backgrounds have become a new idea for precise targeted therapy, but there are still few related studies on pediatric CBF-AML. The author summarizes clinical prognostic impacts of cellular and molecular genetic abnormalities which are commonly seen in pediatric CBF-AML, aiming to provide new ideas for individualized treatment of pediatric CBF-AML.
Key words:
Core binding factors; Leukemia, myeloid, acute; Chromosome aberrations; Prognosis; Child
期刊介绍：
The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
